Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › WV › Charleston › NPI 1891770806
Lab

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings was paid $220.04M by Medicaid between Jan 2018 and Dec 2024, across 203 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 23% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
CHARLESTON, WV 25387
33aNPI1891770806assigned 12/13/2005
33bProvider typeClinical Medical Laboratory
28Total paid$220.04M
24GClaims8,750,297
24DCodes billed203
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in West Virginia

Rank by total paid#1 of 36
Median peer was paid$61K
This provider vs. median3,602×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M$6.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018642,565$15.05M
2019750,024$19.10M
2020900,661$24.34M
20211,323,531$32.39M
20221,779,929$44.48M
20231,848,347$46.88M
2024incomplete1,505,240$37.80M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 23% 1,723,802 1,544,971 $49.72M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 22% 1,726,972 1,543,353 $49.27M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 13% 1,286,495 1,149,989 $28.69M
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 8.9% 536,533 324,849 $19.65M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 8.7% 436,367 387,734 $19.15M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 7.3% 946,659 862,334 $16.09M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 6.6% 631,397 577,851 $14.53M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 2.4% 127,847 115,557 $5.34M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1.9% 63,592 53,837 $4.22M
88141 <1% 159,648 145,487 $1.87M
88142 <1% 112,208 102,025 $1.10M
87086 Culture, bacterial; quantitative colony count, urine <1% 148,353 134,105 $948K
191 more codes
87625 <1% 39,482 $783K
86803 <1% 48,747 $563K
87563 <1% 28,112 $524K
87529 <1% 21,806 $504K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 14,713 $438K
86592 <1% 106,906 $362K
87340 <1% 39,614 $356K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 4,148 $343K
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel <1% 842 $323K
86780 <1% 28,620 $311K
86696 <1% 17,588 $271K
80074 <1% 9,560 $271K
87088 <1% 36,305 $241K
87150 <1% 13,232 $231K
87186 <1% 29,830 $217K
86480 <1% 4,416 $200K
87081 <1% 39,668 $188K
88112 <1% 4,303 $181K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 19,555 $178K
84443 Thyroid stimulating hormone (TSH) <1% 14,514 $173K
86695 <1% 16,446 $164K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 2,155 $134K
87077 <1% 23,255 $117K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 396 $112K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 2,341 $110K
80050 General health panel <1% 3,160 $101K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 7,365 $100K
80081 <1% 2,017 $96K
83036 Hemoglobin; glycosylated (A1C) <1% 16,108 $89K
80053 Comprehensive metabolic panel <1% 12,353 $88K
88173 <1% 1,466 $86K
87255 <1% 3,721 $86K
86706 <1% 9,196 $86K
80061 Lipid panel <1% 11,749 $78K
36415 Collection of venous blood by venipuncture <1% 26,422 $75K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 18,935 $72K
87536 <1% 1,003 $60K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 12,501 $60K
87905 <1% 5,799 $55K
84702 <1% 6,040 $54K
87522 Neg quan hep c or qual rna <1% 1,550 $42K
87102 <1% 5,994 $41K
84146 <1% 3,048 $39K
84439 <1% 6,194 $38K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 576 $38K
86705 <1% 4,015 $38K
83001 <1% 2,706 $37K
87535 <1% 1,584 $35K
86787 <1% 3,047 $34K
84403 <1% 1,863 $34K
86704 <1% 3,287 $32K
81001 <1% 12,542 $29K
87070 <1% 4,443 $25K
82570 <1% 6,439 $24K
82043 <1% 5,675 $21K
82607 <1% 2,335 $20K
82670 <1% 1,365 $20K
83002 <1% 1,790 $18K
86762 <1% 2,044 $18K
86593 <1% 4,636 $16K
84402 <1% 951 $15K
82728 <1% 1,765 $14K
85027 <1% 3,059 $14K
86769 <1% 276 $13K
86850 <1% 2,321 $13K
82746 <1% 1,600 $13K
83013 <1% 353 $12K
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician <1% 2,193 $11K
85018 <1% 5,023 $10K
85014 <1% 4,654 $10K
83550 <1% 1,662 $10K
80361 <1% 926 $9K
80354 <1% 1,405 $9K
86708 <1% 1,055 $8K
87999 <1% 2,051 $8K
83540 <1% 1,789 $8K
86694 <1% 749 $8K
86317 <1% 2,115 $7K
86901 <1% 2,573 $7K
80359 <1% 1,206 $7K
84144 <1% 666 $7K
80348 <1% 1,014 $7K
86900 <1% 2,548 $7K
80349 <1% 789 $6K
80353 <1% 1,086 $6K
81329 <1% 110 $6K
80374 <1% 523 $6K
86003 <1% 99 $6K
80347 <1% 563 $5K
80321 <1% 388 $5K
80325 <1% 485 $5K
87184 <1% 990 $5K
80048 Basic metabolic panel (calcium, ionized) <1% 905 $5K
83655 <1% 456 $4K
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 1,532 $4K
80362 <1% 323 $4K
80346 <1% 310 $4K
80373 <1% 760 $4K
80365 <1% 712 $4K
84703 <1% 720 $4K
87109 <1% 354 $3K
80358 <1% 660 $3K
84436 <1% 823 $3K
82105 <1% 346 $3K
80372 <1% 637 $3K
87480 <1% 223 $3K
83020 <1% 367 $3K
82950 <1% 914 $3K
80324 <1% 468 $3K
87510 <1% 225 $3K
82565 <1% 917 $3K
87660 <1% 234 $3K
82627 <1% 188 $2K
86709 <1% 342 $2K
86038 <1% 264 $2K
87075 <1% 336 $2K
85660 <1% 525 $2K
83021 <1% 151 $2K
84153 <1% 196 $2K
84156 <1% 937 $2K
88164 <1% 262 $2K
81003 <1% 1,142 $2K
86765 <1% 240 $2K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 17 $2K
84479 <1% 495 $2K
86702 <1% 191 $2K
84460 <1% 439 $1K
86735 <1% 119 $1K
86747 <1% 80 $1K
84450 <1% 310 $869.53
83525 <1% 83 $624.31
86336 <1% 82 $611.94
86376 <1% 78 $606.68
82677 <1% 53 $576.20
84481 <1% 55 $551.94
86360 <1% 16 $446.86
83735 <1% 163 $426.33
86701 <1% 53 $389.71
82465 <1% 124 $350.74
88161 <1% 13 $349.44
86140 <1% 120 $331.94
83690 <1% 81 $313.44
85652 <1% 164 $274.05
85610 <1% 76 $243.04
82652 <1% 15 $228.88
82947 <1% 73 $161.82
84163 <1% 18 $151.64
84520 <1% 69 $143.12
82310 <1% 57 $141.05
82977 <1% 44 $128.60
82785 <1% 15 $128.57
88155 <1% 18 $122.03
80356 <1% 13 $115.83
85730 <1% 20 $113.85
86431 <1% 28 $111.39
84295 <1% 39 $97.69
81025 <1% 27 $97.22
83704 <1% 43 $96.50
82248 <1% 35 $93.06
82435 <1% 38 $90.75
84075 <1% 40 $80.13
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 373 $79.95
85379 <1% 54 $76.56
80076 <1% 17 $66.63
82247 <1% 28 $65.01
85384 <1% 44 $63.72
82040 <1% 27 $59.70
83992 <1% 191 $55.84
84550 <1% 14 $51.37
82150 <1% 14 $43.83
80364 <1% 186 $37.16
80367 <1% 187 $34.60
80366 <1% 191 $34.60
80368 <1% 193 $34.48
80355 <1% 192 $34.48
80360 <1% 190 $33.66
80371 <1% 186 $33.11
80357 <1% 188 $33.11
84155 <1% 15 $24.54
80370 <1% 190 $23.36
80341 <1% 186 $22.71
80334 <1% 186 $22.71
80344 <1% 186 $22.71
80337 <1% 186 $22.71
80331 <1% 186 $22.71
80326 <1% 186 $22.71
80377 <1% 186 $22.71
80338 <1% 186 $22.71
83615 <1% 13 $18.11
80305 0% 49 $0.00
87902 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M
Laboratory Corporation of AmericaAlbany, NY$2.06M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.